Form 990 for tax year 2024
Filed by DRAVET SYNDROME FOUNDATION INC.
Totals
- Total revenue
- $4,221,622
- Total expenses
- $4,259,172
- Contributions and grants received
- $3,106,931
- Grants paid
- $2,509,120
- Program service revenue
- $734,789
- Investment income
- $304,376
- Other revenue
- $75,526
- Total assets, end of year
- $8,536,916
- Total liabilities, end of year
- $1,560,863
- Net assets or fund balances, end of year
- $6,976,053
- Program services expenses (Part IX)
- $3,602,910
- Management and general expenses
- $418,901
- Fundraising expenses
- $237,361
- Program service expenses (Part III)
- $3,602,910
Program services were 84.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1a , Federated campaigns
$0
-
1b , Membership dues
$0
-
1c , Fundraising events
$1,412,646
-
1d , Related organizations
$0
-
1e , Government grants (contributions)
$0
-
1f , All other contributions, gifts and grants
$1,694,285
-
1g , Noncash contributions included above
$0
-
2a , Program service revenue: Professional Education & Meetings
total $97,500 · related or exempt $97,500 · unrelated business $0 · excluded $0
-
2b , Program service revenue: Patient & Family Services
total $637,289 · related or exempt $637,289 · unrelated business $0 · excluded $0
-
2f , All other program service revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
3 , Investment income
total $304,376 · related or exempt $0 · unrelated business $0 · excluded $304,376
-
4 , Income from investment of tax-exempt bond proceeds
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
5 , Royalties
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
6c , Rental income or loss
real property $0 · personal property $0
-
7c , Gain or loss
securities $0 · other assets $0
-
8a , Fundraising events: gross income
$377,231
-
8a , Fundraising events: contributions included on line 1c
$1,412,646
-
8b , Fundraising events: direct expenses
$301,705
-
8c , Net income from fundraising events
total $75,526 · unrelated business $0 · excluded $75,526
-
11e , Other revenue, total
$0
Functional expenses
Part IX, the statement of functional expenses.
-
1 , Grants to domestic organizations and governments
total $1,987,617 · program services $1,987,617
-
2 , Grants to domestic individuals
total $22,540 · program services $22,540
-
3 , Grants to foreign organizations and individuals
total $498,963 · program services $498,963
-
5 , Compensation of officers, directors and key employees
total $281,793 · program services $42,846 · management and general $231,432 · fundraising $7,515
-
7 , Other salaries and wages
total $471,622 · program services $283,914 · management and general $38,016 · fundraising $149,692
-
8 , Pension plan contributions
total $26,890 · program services $11,920 · management and general $10,688 · fundraising $4,282
-
10 , Payroll taxes
total $60,970 · program services $26,239 · management and general $21,782 · fundraising $12,949
-
11c , Fees: accounting
total $10,000 · management and general $10,000
-
11g , Fees: other
total $158,070 · program services $122,450 · management and general $35,620 · fundraising $0
-
13 , Office expenses
total $52,271 · program services $10,895 · management and general $19,603 · fundraising $21,773
-
14 , Information technology
total $6,824 · program services $3,266 · management and general $2,469 · fundraising $1,089
-
16 , Occupancy
total $2,643 · program services $881 · management and general $881 · fundraising $881
-
17 , Travel
total $84,526 · program services $69,884 · management and general $7,370 · fundraising $7,272
-
19 , Conferences, conventions and meetings
total $526,603 · program services $512,011 · management and general $10,661 · fundraising $3,931
-
23 , Insurance
total $5,863 · program services $1,747 · management and general $1,512 · fundraising $2,604
-
24a , Other expenses: Bank & Credit Card Fees
total $21,737 · program services $1,366 · management and general $14,522 · fundraising $5,849
-
24b , Other expenses: Charity Registration Fees
total $5,031 · program services $0 · management and general $5,031 · fundraising $0
-
24c , Other expenses: Dues & Subscriptions
total $35,209 · program services $6,371 · management and general $9,314 · fundraising $19,524
Balance sheet
Part X, book values.
-
1 , Cash, non-interest-bearing
beginning of year $369,253 · end of year $383,617
-
2 , Savings and temporary cash investments
beginning of year $571,462 · end of year $1,696,246
-
4 , Accounts receivable
beginning of year $36,608 · end of year $36,352
-
8 , Inventories for sale or use
beginning of year $5,418 · end of year $19,025
-
9 , Prepaid expenses and deferred charges
beginning of year $83,285 · end of year $56,059
-
11 , Investments: publicly traded securities
beginning of year $6,443,876 · end of year $6,345,617
-
17 , Accounts payable and accrued expenses
beginning of year $68,571 · end of year $50,233
-
18 , Grants payable
beginning of year $462,833 · end of year $1,493,749
-
19 , Deferred revenue
beginning of year $63,762 · end of year $16,881
-
25 , Other liabilities
beginning of year $0 · end of year $0
-
27 , Net assets without donor restrictions
beginning of year $6,887,248 · end of year $6,937,386
-
28 , Net assets with donor restrictions
beginning of year $27,488 · end of year $38,667
Mission and programs · 2024
Mission
The mission of the Dravet Syndrome Foundation is to aggressively raise funds for Dravet syndrome & related epilepsies; support & fund research; increase awareness; & provide support to affected individuals & families. We understand the ongoing need to fund innovative research, the urgency in finding better treatments, the motivation of our donors to make an impact specifically in the fields of Dravet syndrome and related epilepsies, the importance of transparency and accountability of not only our organization, but the researchers that we fund, and the need for global collaboration in order to find a cure.
Activities or mission (Part I)
The mission of the Dravet Syndrome Foundation is to aggressively raise funds for Dravet syndrome & related epilepsies; support & fund research; increase awareness; & provide support to affected individuals & families.
-
DSF funds research for better treatments and a cure for Dravet syndrome and related epilepsies by awarding research grants to qualified scientists and clinicians. These grants fund initial research hypotheses that have not been fully explored. The results extracted from this type of research will help bring untested research to the point that it can qualify for larger governmental funding. Since 2009, DSF has awarded over $10.5 million to 71 research endeavors. Research areas include SUDEP, gene therapy, drug discovery, screening, treatments, genetics, epidemiology and neuronal networks. DSF has also supported the development of a commercial line of iPSC cells for researchers and the biotechnology industry. DSF's Scientific Director serves as the liaison between the medical/scientific community and DSF, developing strategies to support research, manage DSF's involvement in projects, and move projects forward with assistance in project management, manuscript preparation, and other writing opportunities. The Scientific Director acts as a representative of DSF to other institutions including NIH, FDA, pharma and biotechnology companies.
Expenses $2,672,460 · Grants $2,485,115
-
Receiving a diagnosis of Dravet syndrome (DS) can be overwhelming, leaving families with many unanswered questions. To support our patient community, DSF provides a variety of educational, advocacy, and support resources: These initiatives are part of DSF's commitment to providing vital resources and fostering a strong, supportive community for those affected by Dravet syndrome. DSF Family Network: Open to any parent, legal guardian, or sibling interested in our advocacy services and programs, the Family Network keeps members informed about new advocacy tools, clinical trials, educational opportunities, and fundraising events. It also includes moderated private Facebook support groups for parents and caregivers of individuals with Dravet syndrome. Membership is limited to those legally responsible for making medical decisions for the patient. In 2024, 347 people joined the Family Network. Newly Diagnosed Kits: DSF provides newly diagnosed families with a kit that includes a guidebook for navigating life after diagnosis, a medication bag, and other materials to ensure they have the knowledge and tools needed for their child's care. In 2024, DSF distributed 131 kits. Patient Assistance Grants: The DSF Patient Assistance Grant Program offers financial support to patients with Dravet syndrome and related SCN1A epilepsies for medical equipment, therapy devices, and educational aids not covered by private insurance or other programs. This program is available to all patients worldwide who are members of the DSF Family Network. Since 2009, DSF has awarded $279,000 to 249 families. Birthday Buddies: Families can register their loved one with Dravet syndrome to receive a birthday card and small gift from DSF's mascot, Aurora, around their birthday. In 2024, DSF sent 640 gifts. Super Siblings Club: DSF provides a day camp at our biennial conference and annual Day of Dravet workshops for siblings of individuals with Dravet syndrome. These events offer a fun and supportive environment for siblings to connect, express their feelings, and bond with others facing similar challenges. Bereavement Support: Losing a loved one, especially a child, is profoundly painful. DSF offers resources for coping with grief, including a Bereavement Support Group and Remembrance Wall. Legislative Advocacy Program: We are committed to keeping our patient community informed about legislative actions affecting Medicaid and rare disease research, which are essential for maintaining access to care and driving advancements in treatment for Dravet syndrome. By ensuring our constituents have accurate and nonpartisan information, they can advocate for their loved one and family effectively. Biennial Conference: This 3-day event brings together families, caregivers, clinicians, researchers, and pharmaceutical professionals to collaborate on improving the lives of those with Dravet syndrome. The conference features presentations on the latest research and patient care, fostering new relationships and collaborations. Over 500 people attended the 2024 conference. Day of Dravet Workshops: Held in alternating years from the biennial conference, these workshops offer families the opportunity to learn about research, treatment options, and connect with others. Sessions are led by community experts, including fellow parents. The workshops also include our VIP Sib Camp and activities for patients. In 2023, over 500 attendees participated at workshops in Colorado (Denver), Florida (Sanford), Connecticut (Stamford), California (Anaheim), and Kentucky (Newport).
Expenses $764,750 · Grants $24,006 · Revenue $637,288
-
DSF produces an annual research roundtable meeting to provide opportunity for researchers and clinicians to collaborate and discuss better treatment options and a roadmap toward a cure and how to best facilitate both. This meeting started in 2010 as a brainstorming session for the few researchers working on Dravet syndrome. DSF hosted its 15th annual Research Roundtable with nearly 190 participants.
Expenses $165,700 · Revenue $97,500
As filed on the 2024 return.
Listed in Part VII
-
Mary Anne Meskis
Executive Director
- Total calculated
- $172,586
- From this org
- $172,586
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $169,586
- Bonus
- $3,000
- Other
- $0
- Deferred
- $6,903
- Nontaxable benefits
- $0
- Filer's total
- $179,489
-
Veronica Hood
Scientific Director
- Total calculated
- $165,459
- From this org
- $165,459
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $164,959
- Bonus
- $500
- Other
- $0
- Deferred
- $6,619
- Nontaxable benefits
- $0
- Filer's total
- $172,078
-
Jamie Cohen
Finance & Program Director
- Total calculated
- $108,866
- From this org
- $108,866
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
-
Ted Odlaug PhD
President
- Total calculated
- $0
- Hours/week
- 1
-
Ross Nicholas
Vice President
- Total calculated
- $0
- Hours/week
- 1
-
Claire Carey
Secretary
- Total calculated
- $0
- Hours/week
- 1
-
Josh Goldman
Treasurer
- Total calculated
- $0
- Hours/week
- 1
-
Nathan Batt
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Ashley Kerns
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Joseph Sullivan MD
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Bill Kirshner
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Gail Farfel
Trustee
- Total calculated
- $0
- Hours/week
- 1
-
Amanda Prather
Trustee
- Total calculated
- $0
- Hours/week
- 1
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Form 990 of other organizations
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
Children's Hospital of Philadelphia
$1,000,000
Individuals with Dravet syndrome (DS) can have different disease courses, and there are important differences in how seizure and development affect them over time. Identifying the causes of variation within the patient population may be helpful in providing accurate prognosis and developing new treatments. This project will generate broad genetic data with whole genome sequencing on 500 individuals with DS. These genetic analyses will be paired with clinical data using pioneered novel methods to transform clinical information to a format that can be used for computational analysis. Finally, this project is built for data sharing - all biosample data, genomic data, and clinical data will be shared within the DS Community.
-
Despite recent advances in small molecule drug discovery, the majority of Dravet syndrome (DS) patients remain intractable and non-seizure symptoms are not addressed. This project aims to exploit an alternative therapeutic strategy that has been successful in mouse models: Medial Ganglionic Eminence (MGE) progenitor cell transplantation to restore healthy fast-spiking interneurons in DS patient brains. While transgenic mice have provided invaluable insights into seizures and some comorbidities associated with DS, mice have critical differences in physiology and neuroanatomy compared to humans and thus are not the most appropriate model to test a cell transplantation-based therapy. In contrast, this study will use rabbits, which are larger vertebrates, more similar to humans. The results of this large animal work will strengthen the preclinical foundation for future cell transplantation therapeutic strategies in DS patients.
-
$250,000
The scientific understanding of how the SCN1A gene changes brain activity is rapidly evolving. This work will explore whether a brain cell that is integrally important in Dravet syndrome symptomatology has disruptions that lead to specific malfunctions. This work aims to determine how mutations in the SCN1A gene impact these cells' normally powerful ability to "put the brakes on" the brain when it is too active. We believe that the loss of this "brake" may lead to seizures, and our experiments may yield important clues about how to get it working again.
-
Mutations in the SCN1A gene most commonly cause reduced functioning of the Nav1.1 protein and lead to Dravet syndrome, a debilitating epilepsy disorder. However, a new class of SCN1A mutations causes excessive activity of Nav1.1. Individuals with these mutations exhibit an even more severe form of epilepsy as well as developmental delay and intellectual disability. This research group has generated the first mouse expressing a patient-derived mutation associated with this severe early-onset condition. In this fellowship, they will evaluate the novel mouse for neurological abnormalities, including seizures and movement disorders. Additionally, they will investigate the electrical properties of neurons. The overall goal is to understand the mechanism by which both reduced and excessive activity of Nav1.1 can cause epilepsy and to identify treatments for both disorders.
-
$75,000
Current precision therapeutic clinical trials for Dravet syndrome (DS) utilize seizure frequency as the primary outcome measure, but using this alone to assess outcome does not capture the full array of challenges associated with DS. This project will focus on refining a set of clinician and caregiver-reported outcome measures previously created for CDKL5-deficiency disorder and piloting them in patients with DS. The overarching objective is to design valid and feasible outcome measures specifically for DS that represent the full range of the phenotype. The creation of the DS clinical severity assessment-clinician and caregiver (DS-CSA) will be a crucial step towards disease modifying clinical trial readiness in DS.
-
Individuals with Dravet syndrome (DS) suffer from severe seizures that cannot be completely controlled by medications. While most epilepsy research has focused on the more superficial brain regions that we know are prone to seizures, an improved understanding of the role of deeper brain regions in epilepsy may open the door to new therapies. The focus of this proposal is a deep brain region called the locus coeruleus, which sends noradrenergic projections throughout seizure-prone brain regions. The locus coeruleus is known as a "master regulator" that coordinates brain-wide states, such as reward and attention; this project will test the hypothesis that it also plays a critical role in seizures in DS using a mouse model of DS, to (1) determine the activity of noradrenergic neurons during seizures and (2) test whether their activation curtails seizures.
-
This project aims to establish a biobank of five unique lines of commercially-available induced pluripotent stem cells (iPSCs) from patient blood samples. The cellular reprogramming will be conducted by the Coriell Institute for Medical Research and samples will be housed and distributed through an additional partnership with the Orphan Disease Center at The University of Pennsylvania. Cell lines will be available to researchers in academic and for-profit research settings at a low cost, set to cover the long-term maintenance of the biobank effort.
Fundraising and gaming
From Schedule G of this return, as filed.
- Had an agreement with a professional fundraiser (line 2a)
- Not answered
Fundraising events (Part II)
Part II has at most four columns: the two largest events, the rest together, and the total.
| Line | Event 1 Dance for Dravet | Event 2 A Night Under the Stars | Other events 22 events | Total |
|---|---|---|---|---|
| Gross receipts (line 1) | $563,601 | $341,118 | $885,158 | $1,789,877 |
| Less contributions (line 2) | $430,926 | $256,785 | $724,935 | $1,412,646 |
| Gross income (line 3) | $132,675 | $84,333 | $160,223 | $377,231 |
| Cash prizes (line 4) | $0 | $0 | $0 | $0 |
| Noncash prizes (line 5) | $0 | $0 | $0 | $0 |
| Rent and facility costs (line 6) | $5,381 | $0 | $11,533 | $16,914 |
| Food and beverages (line 7) | $62,339 | $41,207 | $45,553 | $149,099 |
| Entertainment (line 8) | $6,716 | $4,350 | $10,925 | $21,991 |
| Other direct expenses (line 9) | $21,366 | $22,600 | $69,735 | $113,701 |
- Direct expenses (line 10)
- $301,705
- Net income (line 11)
- $75,526
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $498,963
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| Europe (including Iceland and Greenland) | 0 | 0 | Grantmaking | Research grants. | $250,000 |
| North America (including Canada and Mexico, but not the United States) | 0 | 0 | Grantmaking | Research grants. | $248,963 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| Europe (including Iceland and Greenland) | $250,000 | Wire Transfer | $0 | — | FMV |
| North America (including Canada and Mexico, but not the United States) | $247,498 | Wire Transfer | — | — | FMV |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 2
- Other grantees (Part II line 3)
- 0
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 22 April 2025
- IRS schema version
- 2024v5.0
- Source object
- 202521139349301012
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.